Sanctuary Advisors LLC Raises Holdings in IDEXX Laboratories, Inc. $IDXX

Sanctuary Advisors LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,364 shares of the company’s stock after buying an additional 1,628 shares during the period. Sanctuary Advisors LLC’s holdings in IDEXX Laboratories were worth $8,071,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. Harbour Investments Inc. increased its stake in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after acquiring an additional 16 shares during the last quarter. CWA Asset Management Group LLC boosted its position in shares of IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after acquiring an additional 17 shares during the last quarter. Rockland Trust Co. grew its holdings in shares of IDEXX Laboratories by 4.4% in the fourth quarter. Rockland Trust Co. now owns 425 shares of the company’s stock valued at $288,000 after purchasing an additional 18 shares in the last quarter. Prime Capital Investment Advisors LLC grew its holdings in shares of IDEXX Laboratories by 0.5% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock valued at $2,654,000 after purchasing an additional 18 shares in the last quarter. Finally, Pinnacle Associates Ltd. increased its position in IDEXX Laboratories by 1.5% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock worth $830,000 after purchasing an additional 18 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on IDXX. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group decreased their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup began coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Down 1.5%

IDXX opened at $567.44 on Friday. IDEXX Laboratories, Inc. has a one year low of $513.02 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a market cap of $44.76 billion, a price-to-earnings ratio of 41.78, a P/E/G ratio of 3.15 and a beta of 1.55. The stock’s 50 day moving average price is $554.49 and its 200-day moving average price is $599.94.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.